Page last updated: 2024-09-03

gefitinib and sc 236

gefitinib has been researched along with sc 236 in 2 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (sc 236)	Trials (sc 236)	Recent Studies (post-2010) (sc 236)
5,231	566	2,919	147	0	25

Protein Interaction Comparison

Protein	Taxonomy	gefitinib (IC50)	sc 236 (IC50)
Prostaglandin G/H synthase 2	Homo sapiens (human)		0.0081
Prostaglandin G/H synthase 2	Mus musculus (house mouse)		0.01

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM	1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Melisi, D; Tortora, G; Veneziani, BM	1

Other Studies

2 other study(ies) available for gefitinib and sc 236

Article	Year
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4 Topics: Agar; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Isoenzymes; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Prostaglandin-Endoperoxide Synthases; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Sulfonamides	2003
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocrine-related cancer, 2005, Volume: 12, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid	2005

Article

Year

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4

Topics: Agar; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Isoenzymes; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Prostaglandin-Endoperoxide Synthases; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Sulfonamides

2003

Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.

Endocrine-related cancer, 2005, Volume: 12, Issue:4

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid

2005